Shots:

• Chi-Med to receive ~$95M and ~$135M as development & commercial milestones along with royalties on commercialization of each drug candidates. Inmagene to get an exclusive option for four drug candidates solely for immunological diseases
• If Inmagene exercises the option- it will get the right to further develop- manufacture and commercialize the specific drug candidate globally- with Chi-Med retaining the first right to co-commercialization it in mainland China
• The companies will work together to move the drug candidates towards IND submission. If successful- Inmagene will further lead drug candidates through global clinical development

 ­ Ref: ChiMed | Image: Inmagenebio